Manni Mohyuddin on DREAMM-7

Manni Mohyuddin shared on X/Twitter:

“In DREAMM-7 (bela/bort/dex vs dara/bort/dex).

• Only 34% of pts len refractory.
• POLLUX trial showed PFS of 45 months with dara/len/dex
• Would bela/velcade/dex (PFS=37 mo) beat DRd for len sensitive patients?

Answer is clear:

If len/dara sensitive at relapse, use dara/len/dex!

I do not think we will get such results with Bela/bortezomib/dex in a US population that is increasing both Dara and Len refractory at first relapse.

PFS will likely be very modest.

Some food for a (controversial thought). How much PFS2 do we sacrifice with our current approach to treating myeloma?”

Source: Manni Mohyuddin/X

Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.